Regulation of Breast Cancer Stem Cell Activity by Signaling Through the Notch4 Receptor

Overview

Journal Cancer Res

Specialty Oncology

Date 2010 Jan 14

PMID 20068161

Citations 286

Authors

Hannah Harrison

Gillian Farnie

Sacha J Howell

Rebecca E Rock

Spyros Stylianou

Keith R Brennan

Nigel J Bundred

Robert B Clarke

Affiliations

Soon will be listed here.

Abstract

Notch receptor signaling pathways play an important role not only in normal breast development but also in breast cancer development and progression. We assessed the role of Notch receptors in stem cell activity in breast cancer cell lines and nine primary human tumor samples. Stem cells were enriched by selection of anoikis-resistant cells or cells expressing the membrane phenotype ESA(+)/CD44(+)/CD24(low). Using these breast cancer stem cell populations, we compared the activation status of Notch receptors with the status in luminally differentiated cells, and we evaluated the consequences of pathway inhibition in vitro and in vivo. We found that Notch4 signaling activity was 8-fold higher in stem cell-enriched cell populations compared with differentiated cells, whereas Notch1 signaling activity was 4-fold lower in the stem cell-enriched cell populations. Pharmacologic or genetic inhibition of Notch1 or Notch4 reduced stem cell activity in vitro and reduced tumor formation in vivo, but Notch4 inhibition produced a more robust effect with a complete inhibition of tumor initiation observed. Our findings suggest that Notch4-targeted therapies will be more effective than targeting Notch1 in suppressing breast cancer recurrence, as it is initiated by breast cancer stem cells.

Citing Articles

Triple-positive breast cancer: navigating heterogeneity and advancing multimodal therapies for improving patient outcomes.

Xie J, Yang Z, Li Z, Zhang T, Chen H, Chen X Cancer Cell Int. 2025; 25(1):77.

PMID: 40045297 PMC: 11881339. DOI: 10.1186/s12935-025-03680-7.

Classification of Breast Cancer Through the Perspective of Cell Identity Models.

Iggo R, MacGrogan G Adv Exp Med Biol. 2025; 1464():185-207.

PMID: 39821027 DOI: 10.1007/978-3-031-70875-6_11.

DOT1L Mediates Stem Cell Maintenance and Represents a Therapeutic Vulnerability in Cancer.

Kurani H, Kurani H, Slingerland J Cancer Res. 2024; 85(5):838-847.

PMID: 39700409 PMC: 11873724. DOI: 10.1158/0008-5472.CAN-24-3304.

PRMT5-regulated splicing of DNA repair genes drives chemoresistance in breast cancer stem cells.

Gillespie M, Chiang K, Regan-Mochrie G, Choi S, Ward C, Sahay D Oncogene. 2024; .

PMID: 39695328 DOI: 10.1038/s41388-024-03264-1.

Advances in the Understanding of the Pathogenesis of Triple-Negative Breast Cancer.

Liu Y, Zou Y, Ye Y, Chen Y Cancer Med. 2024; 13(22):e70410.

PMID: 39558881 PMC: 11574469. DOI: 10.1002/cam4.70410.

References

Stylianou S, Clarke R, Brennan K . Aberrant activation of notch signaling in human breast cancer. Cancer Res. 2006; 66(3):1517-25. DOI: 10.1158/0008-5472.CAN-05-3054. View

Dick J . Normal and leukemic human stem cells assayed in SCID mice. Semin Immunol. 1996; 8(4):197-206. DOI: 10.1006/smim.1996.0025. View

Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison S, Clarke M . Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100(7):3983-8. PMC: 153034. DOI: 10.1073/pnas.0530291100. View

Ricci-Vitiani L, Lombardi D, Pilozzi E, Biffoni M, Todaro M, Peschle C . Identification and expansion of human colon-cancer-initiating cells. Nature. 2006; 445(7123):111-5. DOI: 10.1038/nature05384. View

Rizzo P, Miao H, DSouza G, Osipo C, Song L, Yun J . Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res. 2008; 68(13):5226-35. PMC: 4445363. DOI: 10.1158/0008-5472.CAN-07-5744. View

Dickson B, Mulligan A, Zhang H, Lockwood G, OMalley F, Egan S . High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol. 2007; 20(6):685-93. DOI: 10.1038/modpathol.3800785. View

DeFriend D, Anderson E, Bell J, Wilks D, West C, Mansel R . Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro. Br J Cancer. 1994; 70(2):204-11. PMC: 2033516. DOI: 10.1038/bjc.1994.281. View

Pece S, Serresi M, Santolini E, Capra M, Hulleman E, Galimberti V . Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol. 2004; 167(2):215-21. PMC: 2172557. DOI: 10.1083/jcb.200406140. View

Phillips T, McBride W, Pajonk F . The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006; 98(24):1777-85. DOI: 10.1093/jnci/djj495. View

10.

Li X, Lewis M, Huang J, Gutierrez C, Osborne C, Wu M . Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008; 100(9):672-9. DOI: 10.1093/jnci/djn123. View

11.

Shipitsin M, Campbell L, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J . Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007; 11(3):259-73. DOI: 10.1016/j.ccr.2007.01.013. View

12.

Imatani A, Callahan R . Identification of a novel NOTCH-4/INT-3 RNA species encoding an activated gene product in certain human tumor cell lines. Oncogene. 2000; 19(2):223-31. DOI: 10.1038/sj.onc.1203295. View

13.

Singh S, Hawkins C, Clarke I, Squire J, Bayani J, Hide T . Identification of human brain tumour initiating cells. Nature. 2004; 432(7015):396-401. DOI: 10.1038/nature03128. View

14.

Raouf A, Zhao Y, To K, Stingl J, Delaney A, Barbara M . Transcriptome analysis of the normal human mammary cell commitment and differentiation process. Cell Stem Cell. 2008; 3(1):109-18. DOI: 10.1016/j.stem.2008.05.018. View

15.

Clarke R, Spence K, Anderson E, Howell A, Okano H, Potten C . A putative human breast stem cell population is enriched for steroid receptor-positive cells. Dev Biol. 2004; 277(2):443-56. DOI: 10.1016/j.ydbio.2004.07.044. View

16.

Weijzen S, Rizzo P, Braid M, Vaishnav R, Jonkheer S, Zlobin A . Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med. 2002; 8(9):979-86. DOI: 10.1038/nm754. View

17.

Sleeman K, Kendrick H, Ashworth A, Isacke C, Smalley M . CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells. Breast Cancer Res. 2006; 8(1):R7. PMC: 1413978. DOI: 10.1186/bcr1371. View

18.

Ginestier C, Hur M, Charafe-Jauffret E, Monville F, Dutcher J, Brown M . ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2008; 1(5):555-67. PMC: 2423808. DOI: 10.1016/j.stem.2007.08.014. View

19.

Collins A, Berry P, Hyde C, Stower M, Maitland N . Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005; 65(23):10946-51. DOI: 10.1158/0008-5472.CAN-05-2018. View

20.

Bouras T, Pal B, Vaillant F, Harburg G, Asselin-Labat M, Oakes S . Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. Cell Stem Cell. 2008; 3(4):429-41. DOI: 10.1016/j.stem.2008.08.001. View